Huntsman Carole 4
4 · MADRIGAL PHARMACEUTICALS, INC. · Filed Jan 26, 2026
Research Summary
AI-generated summary of this filing
Madrigal (MDGL) CCO Carole Huntsman Sells Shares
What Happened
- Carole Huntsman, Chief Commercial Officer of Madrigal Pharmaceuticals (MDGL), sold a total of 910 shares in two open-market transactions on January 26, 2026, generating gross proceeds of approximately $449,339. The sales were: 340 shares at $492.42 ($167,423) and 570 shares at $494.59 ($281,916). These were sales (not purchases) and sales by insiders are often routine.
Key Details
- Transaction dates and prices:
- 2026-01-26: 340 shares sold at $492.42 — $167,423 (Footnote F1)
- 2026-01-26: 570 shares sold at $494.59 — $281,916 (Footnote F2)
- Combined total: 910 shares for ~$449,339.
- Shares owned after transaction: Not reported in the provided Form 4 excerpt.
- Footnotes:
- F1: The 340-share sale was an automatic sale by the issuer to cover tax withholding on vested restricted stock units (not at the Reporting Person’s discretion).
- F2: The 570-share sale was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on Nov 5, 2024.
- Filing timeliness: No indication in the provided data that the filing was late.
Context
- These transactions include a tax-withholding disposition and a planned sale under a 10b5-1 plan. Such sales are commonly procedural and do not, by themselves, indicate the insider’s view of the company’s prospects.
Insider Transaction Report
Form 4
Huntsman Carole
Chief Commercial Officer
Transactions
- Sale
Common Stock
[F1]2026-01-26$492.42/sh−340$167,423→ 9,692 total - Sale
Common Stock
[F2]2026-01-26$494.59/sh−570$281,916→ 9,122 total
Footnotes (2)
- [F1]The sale reported on this line represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.
- [F2]This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.
Signature
/s/ Mardi Dier, as Attorney-in-Fact|2026-01-26